Treatment to prevent Alzheimer’s disease moves a step closer

A new drug to prevent the early stages of Alzheimer’s disease could enter clinical trials in a few years’ time according to scientists.

Alzheimer’s is the most common type of dementia, which currently affects 820,000 people in the UK, with numbers expected to more than double by 2050. One in three people over 65 will die with dementia.

The disease begins when a protein called amyloid-β (Aβ) starts to clump together in senile plaques in the brain, damaging nerve cells and leading to memory loss and confusion.

Professor David Allsop and Dr Mark Taylor at Lancaster University have successfully created a new drug which can reduce the number of senile plaques by a third, as well as more than doubling the number of new nerve cells in a particular region of the brain associated with memory.  It also markedly reduced the amount of brain inflammation and oxidative damage associated with the disease.

The drug was tested on transgenic mice containing two mutant human genes linked to inherited forms of Alzheimer’s, so that they would develop some of the changes associated with the illness. The drug is designed to cross the blood-brain barrier and prevent the Aβ molecules from sticking together to form plaques.

Professor Allsop, who led the research and was the first scientist to isolate senile plaques from human brain, said: “When we got the test results back, we were highly encouraged. The amount of plaque in the brain had been reduced by a third and this could be improved if we gave a larger dose of the drug, because at this stage, we don’t know what the optimal dose is.”

The drug needs to be tested for safety before it can enter human trials, but, if it passes this hurdle, the aim would be to give the drug to people with mild symptoms of memory loss before they develop the illness.

“Many people who are mildly forgetful may go on to develop the disease because these senile plaques start forming years before any symptoms manifest themselves. The ultimate aim is to give the drug at that stage to stop any more damage to the brain, before it’s too late.”

Support for the research was given by Alzheimer’s Research UK, and the results are published in the open access journal PLOS ONE.

Expert psychologist suggests the era of genius scientists is over

Dean Keith Simonton, a psychology professor at the University of California, has published a comment piece in the journal Nature, where he argues that it’s unlikely mankind will ever produce another Einstein, Newton, Darwin, etc. This is because, he says, we’ve already discovered all the most basic ideas that describe how the natural world works. Any new work, will involve little more than adding to our knowledge base.

Simonton’s comments are likely to draw a strong reaction, both in and out of the science world. It’s been the geniuses among us that have driven science forward for thousands of years, after all. If no more geniuses appear to offer an entirely new way of looking at things, how will the human race ever reach new heights?

Simonton has been studying geniuses and their contributions to science for more than 30 years and has even written books on them. He also writes that he hopes he is wrong in his assessment, even as he clearly doesn’t think he is. Sadly, the past several decades only offer proof. Since the time of Einstein, he says, no one has really come up with anything that would mark them as a giant in the field, to be looked up to hundreds, if not thousands of years from now. Worse perhaps, he details how the way modern science is conducted is only adding to the problem. Rather than fostering lone wolves pondering the universe in isolation, the new paradigm has researchers working together as teams, efficiently going about their way, marching towards incremental increases in knowledge. That doesn’t leave much room for true insight, which is of course, a necessary ingredient for genius level discoveries.

Simonton could be wrong of course – there might yet be some person that looks at all that has been discovered and compares it with his or her own observations, and finds that what we think we know, is completely wrong, and offers evidence of something truly groundbreaking as an alternative. The study of astrophysics, for example, appears ripe for a new approach. Scientists are becoming increasingly frustrated in trying to explain why the universe is not just expanding, but is doing so at an increasing rate. Perhaps most of the theories put forth over the past half-century or so, are completely off base. Modern science can’t even explain gravity, after all. Isn’t it possible that there is something at work that will need the intelligence, insight and courage of an Einstein to figure out? It appears we as a species are counting on it, even as we wonder if it’s even possible.

Bonobos predisposed to show sensitivity to others

Comforting a friend or relative in distress may be a more hard-wired behavior than previously thought, according to a new study of bonobos, which are great apes known for their empathy and close relation to humans and chimpanzees. This finding provides key evolutionary insight into how critical social skills may develop in humans. The results are published in the online journal PLOS ONE.

Researchers from the Yerkes National Primate Research Center, Emory University, observed juvenile bonobos at the Lola ya Bonobo sanctuary in the Democratic Republic of Congo engaging in consolation behavior more than their adult counterparts. Juvenile bonobos (ages 3 to 7) are equivalent to preschool or elementary school-aged children.

Zanna Clay, PhD, a postdoctoral fellow in Emory’s Department of Psychology, and Frans de Waal, PhD, director of the Living Links Center at Yerkes and C.H. Candler Professor of Psychology at Emory, led the study.

"Our findings suggest that for bonobos, sensitivity to the emotions of others emerges early and does not require advanced thought processes that develop only in adults," Clay says.

Starting at around age two, human children usually display consolation behavior, a sign of sensitivity to the emotions of others and the ability to take the perspective of another. Consolation has been observed in humans, bonobos, chimpanzees and other animals, including dogs, elephants and some types of birds, but has not been seen in monkeys.

At the Lola ya Bonobo sanctuary, most bonobos come as juvenile or infant orphans because their parents are killed for meat or captured as pets. A minority of bonobos in the sanctuary is second generation and raised by their biological mothers. The researchers found bonobos raised by their own mothers were more likely to comfort others compared to orphaned bonobos. This may indicate early life stress interferes with development of consolation behavior, while a stable parental relationship encourages it, Clay says.

Clay observed more than 350 conflicts between bonobos at the sanctuary during several months. Some conflicts involved violence, such as hitting, pushing or grabbing, while others only involved threats or chasing. Consolation occurred when a third bonobo – usually one that was close to the scene of conflict – comforted one of the parties in the conflict.

Consolation behavior includes hugs, grooming and sometimes sexual behavior. Consolation appears to lower stress in the recipient, based on a reduction in the recipient’s rates of self-scratching and self-grooming, the authors write.

"We found strong effects of friendship and kinship, with bonobos being more likely to comfort those they are emotionally close to," Clay says. "This is consistent with the idea that empathy and emotional sensitivity contribute to consolation behavior."

In future research, Clay plans to take a closer look at the emergence of consolation behavior in bonobos at early ages. A process that may facilitate development of consolation behavior is when older bonobos use younger ones as teddy bears; their passive participation may get the younger bonobos used to the idea, she says.

(Image: Getty)

The Star-Nosed Mole Reveals Clues to the Molecular Basis of Mammalian Touch

Little is known about the molecular mechanisms underlying mammalian touch transduction. To identify novel candidate transducers, we examined the molecular and cellular basis of touch in one of the most sensitive tactile organs in the animal kingdom, the star of the star-nosed mole. Our findings demonstrate that the trigeminal ganglia innervating the star are enriched in tactile-sensitive neurons, resulting in a higher proportion of light touch fibers and lower proportion of nociceptors compared to the dorsal root ganglia innervating the rest of the body. We exploit this difference using transcriptome analysis of the star-nosed mole sensory ganglia to identify novel candidate mammalian touch and pain transducers. The most enriched candidates are also expressed in mouse somatosesensory ganglia, suggesting they may mediate transduction in diverse species and are not unique to moles. These findings highlight the utility of examining diverse and specialized species to address fundamental questions in mammalian biology.

Full article

Cognitive Connectivity

Credit: Emmett McQuinn, Theodore M. Wong, Pallab Datta, Myron D. Flickner, Raghavendra Singh, Steven K. Esser, Rathinakumar Appuswamy, William P. Risk, and Dharmendra S. Modha; IBM Research - Almaden  -(First place winners in the illustration category of the 2012 International Science & Engineering Visualization Challenge)

Cognitive Computing researchers at IBM are developing a new generation of “neuro-synaptic” computer chips inspired by the organization and function of the brain. For guidance into how to connect many such chips in a large brain-like network, they turn to a “wiring diagram” of the monkey brain as represented by the CoCoMac database. In a simulation designed to test techniques for constructing such networks, a model was created comprising 4173 neuro-synaptic “cores” representing the 77 largest regions in the macaque brain. The 320749 connections between the regions were assigned based on the CoCoMac wiring diagram. This visualization is of the resulting core-to-core connectivity graph. Each core is represented as an individual point along the ring; their arrangement into local clusters reflects their assignment to the 77 regions. Arcs are drawn from a source core to a destination core with an edge color defined by the color assigned to the source core.

Owl Mystery Unraveled: Scientists Explain How Bird Can Rotate Its Head Without Cutting Off Blood Supply to Brain

Medical illustrators and neurological imaging experts at Johns Hopkins have figured out how night-hunting owls can almost fully rotate their heads - by as much as 270 degrees in either direction - without damaging the delicate blood vessels in their necks and heads, and without cutting off blood supply to their brains.

In what may be the first use of angiography, CT scans and medical illustrations to examine the anatomy of a dozen of the big-eyed birds, the Johns Hopkins team, led by medical illustrator Fabian de Kok-Mercado, M.A., a recent graduate student in the Department of Art as Applied to Medicine, found four major biological adaptations designed to prevent injury from rotational head movements. The variations are all to the strigid animals’ bone structure and vascular network needed to support its top-heavy head. The team’s findings are acknowledged in the Feb.1 issue of the journal Science, as first-place prize winners in the posters and graphics category of the National Science Foundation’s 2012 International Science & Engineering Visualization Challenge.

Researcher uncovers potential cause, biomarker for autism and proposes study to investigate theory

A New York-based physician-researcher from Touro College of Osteopathic Medicine, best known for his research into fertility and twinning, has uncovered a potential connection between autism and a specific growth protein that could eventually be used as a way to predict an infant’s propensity to later develop the disease. The protein, called insulin-like growth factor (IGF), is especially involved in the normal growth and development of babies’ brain cells. Based on findings of prior published studies, Touro researcher Gary Steinman, MD, PhD, proposes that depressed levels of this protein in the blood of newborns could potentially serve as a biomarker for the later development of autism. However, this connection, described below in greater detail, has never been directly studied. Steinman presents his exciting theory in the journal Medical Hypotheses.

IGF stimulates special cells in the brain to provide an essential insulating material, called myelin, around the developing nerves that is needed to efficiently transmit important messages about everything the brain controls — from physical functions such as movement to mental functions such as sensory perception, thinking and emotions. In the developing fetal and pediatric brain, myelin is also important for nerve fibers in one area of the brain to form proper pathways to other regions, allowing the body to hone functions over time. Insufficient IGF results in insufficient insulating material, as has been seen in brain biopsies of autistic individuals, and may impede proper pathway development. Steinman is proposing that this potential relationship between neonatal IGF levels and autism be directly studied.

"Autism is on the rise, especially in the last two decades — either because of environmental factors, expanded diagnostic criteria, or both. Yet almost nothing is currently known about the predisposing molecular and histological changes that differentiate a newborn destined to be neurologically normal from an autistic one," said Steinman.

Because no effective treatment or prevention for autism exists, research examining Steinman’s idea is critical, as it may hold the key to understanding the cause of this often devastating illness. In his article, Steinman proposes a study to investigate this hypothesis, and if this study supports his theory that identification of reduced IGF at birth is later followed by the appearance of autistic characteristics, then the subsequent development of a simple biomarker blood test is equally critical.

Discovery opens the door to a potential ‘molecular fountain of youth’

A new study led by researchers at the University of California, Berkeley, represents a major advance in the understanding of the molecular mechanisms behind aging while providing new hope for the development of targeted treatments for age-related degenerative diseases.

Researchers were able to turn back the molecular clock by infusing the blood stem cells of old mice with a longevity gene and rejuvenating the aged stem cells’ regenerative potential. The findings were published online in the journal Cell Reports.

The biologists found that SIRT3, one among a class of proteins known as sirtuins, plays an important role in helping aged blood stem cells cope with stress. When they infused the blood stem cells of old mice with SIRT3, the treatment boosted the formation of new blood cells, evidence of a reversal in the age-related decline in the old stem cells’ function.

“We already know that sirtuins regulate aging, but our study is really the first one demonstrating that sirtuins can reverse aging-associated degeneration, and I think that’s very exciting,” said study principal investigator Danica Chen, UC Berkeley assistant professor of nutritional science and toxicology. “This opens the door to potential treatments for age-related degenerative diseases.”